# Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)

> **NCT00048724** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 631 (actual)

## Conditions studied

- Chronic Hepatitis C
- Cirrhosis

## Interventions

- **BIOLOGICAL:** peginterferon alfa-2b (SCH 54031)

## Key facts

- **NCT ID:** NCT00048724
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 631 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00048724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00048724, "Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00048724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*